



26 May 2009
BioPharmica (ASX: BPH) ASX Announcement

HLS5 PROJECT AWARDED GRANT FOR MELANOMA RESEARCH

HLS5 Senior Researcher Dr Louise Winteringham has received \$50,000 from the Scott Kirkbride Melanoma Research Centre (SKMRC). Thanks to the grant, Dr Winteringham will now lead a team at Western Australian Institute for Medical Research (WAIMR) investigating the tumor suppressor gene HLS5 and its potential influence in melanoma.

“We have already uncovered a role for HLS5 in leukemia and breast cancer, and during that process we noticed that the gene also interacts with a number of key proteins involved in one of the known growth pathways associated with melanoma,” she said.

“So far, we’ve found that HLS5 influences the levels of proteins affecting the growth of certain cancer cells, so we will now work to find out whether this is the case for melanoma”.

“Ultimately, we hope to be able to pinpoint a target for correcting the defect that contributes to melanoma cell growth.”

BioPharmica has exclusive rights to the tumor suppressor gene ‘HLS5’ and has been investing in the project since 2004. The HLS5 tumour suppressor gene was reported by WAIMR Director Professor Peter Klinken.

Yours sincerely,

David Breeze
Chairman

For more information contact:

Mr David Breeze
Chairman
BioPharmica Limited
Tel : +61 9 9328 8366



Scott Kirkbride Melanoma Research Centre

SKMRC

